ArticlePloS one2012
Characterizing the network of drugs and their affected metabolic subpathways.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 38 citations in OpenAlex.
- The implementation of drug reposition for alcoholic hepatitis based on a sub-pathway integration strategy.Annals of translational medicine · 2020Article
- Construction and Analysis of Human Diseases and Metabolites Network.Frontiers in bioengineering and biotechnology · 2020Article
- System level characterization of small molecule drugs and their affected long noncoding RNAs.Aging · 2019Article
- Identifying cancer-related microRNAs based on subpathways.IET systems biology · 2018Article
- Pathway networks generated from human disease phenome.BMC medical genomics · 2018Article
- Identification of a robust subpathway-based signature for acute myeloid leukemia prognosis using an miRNA integrated strategy.PloS one · 2018Article
- Integrating gene and lncRNA expression to infer subpathway activity for tumor analyses.Oncotarget · 2017Article
- sPAGM: inferring subpathway activity by integrating gene and miRNA expression-robust functional signature identification for melanoma prognoses.Scientific reports · 2017Article
- Identification of candidate drugs for the treatment of metastatic osteosarcoma through a subpathway analysis method.Oncology letters · 2017Article
- Detecting Disease Specific Pathway Substructures through an Integrated Systems Biology Approach.Non-coding RNA · 2017Article
- Subpathway-CorSP: Identification of metabolic subpathways via integrating expression correlations and topological features between metabolites and genes of interest within pathways.Scientific reports · 2016Article
- Integrating subpathway analysis to identify candidate agents for hepatocellular carcinoma.OncoTargets and therapy · 2016Article
- A subpathway-based method of drug reposition for polycystic ovary syndrome.Reproductive sciences (Thousand Oaks, Calif.) · 2015Article
- Cofunctional Subpathways Were Regulated by Transcription Factor with Common Motif, Common Family, or Common Tissue.BioMed research international · 2015Article
- Article
- Functional analysis of the mRNA profile of neutrophil gelatinase‑associated lipocalin overexpression in esophageal squamous cell carcinoma using multiple bioinformatic tools.Molecular medicine reports · 2014Article
- A sub-pathway based method to identify candidate drugs for glioblastomas.Medical oncology (Northwood, London, England) · 2014Article
- Metabolomics and systems pharmacology: why and how to model the human metabolic network for drug discovery.Drug discovery today · 2014Review
- Article
- Subpathway-GM: identification of metabolic subpathways via joint power of interesting genes and metabolites and their topologies within pathways.Nucleic acids research · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A fundamental issue in biology and medicine is illustration of the overall drug impact which is always the consequence of changes in local regions of metabolic pathways (subpathways). To gain insights into the global relationship between drugs and their affected metabolic subpathways, we constructed a drug-metabolic subpathway network (DRSN). This network included 3925 significant drug-metabolic subpathway associations representing drug dual effects. Through analyses based on network biology, we found that if drugs were linked to the same subpathways in the DRSN, they tended to share the same indications and side effects. Furthermore, if drugs shared more subpathways, they tended to share more side effects. We then calculated the association score by integrating drug-affected subpathways and disease-related subpathways to quantify the extent of the associations between each drug class and disease class. The results showed some close drug-disease associations such as sex hormone drugs and cancer suggesting drug dual effects. Surprisingly, most drugs displayed close associations with their side effects rather than their indications. To further investigate the mechanism of drug dual effects, we classified all the subpathways in the DRSN into therapeutic and non-therapeutic subpathways representing drug therapeutic effects and side effects. Compared to drug side effects, the therapeutic effects tended to work through tissue-specific genes and these genes tend to be expressed in the adrenal gland, liver and kidney; while drug side effects always occurred in the liver, bone marrow and trachea. Taken together, the DRSN could provide great insights into understanding the global relationship between drugs and metabolic subpathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.